Related Experiment Video
Updated: Mar 15, 2026
10:08
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
Published on: February 17, 2018
14.1K
Thymopentin improves cardiac function in older patients with chronic heart failure
Cao Xiaojing1, Li Yanfang2, Guo Yanqing1
1Division of Cardiology, Beijing Anzhen Hospital, Capital Medical University; Beijing-China.
Anatolian Journal of Cardiology
|August 27, 2016
Summary
Immune modulation therapy with thymopentin improved cardiac function in older adults with chronic heart failure (CHF). This treatment regulated lymphocyte subsets and inflammatory cytokines, offering a new approach for CHF management.
Area of Science:
- Cardiology
- Immunology
- Geriatrics
Background:
- Heart failure (HF) development is linked to immune system activation, inflammation, and mediator release.
- Understanding immune system modulation's role in HF is crucial for developing effective therapies.
Purpose of the Study:
- To investigate if regulating lymphocyte subsets and cytokines can improve cardiac function in older patients with chronic heart failure (CHF).
- To assess the efficacy of thymopentin in modulating immune responses and improving clinical outcomes in CHF.
Main Methods:
- Ninety-six elderly patients with CHF were randomized into a testing group (regular therapy + thymopentin) and a control group (regular therapy).
- Cardiac function (LVEF, LVEDD, LVESD), inflammatory markers (hsCRP, BNP), exercise capacity (6MWT), quality of life (MLHFQ), lymphocyte subsets (CD3+, CD4+, CD8+, NK cells), and cytokines (IL-10, TNF-α, IL-1β) were measured.
- A group of 45 healthy elderly individuals served as normal controls.
Main Results:
- Thymopentin treatment significantly increased left ventricular ejection fraction (LVEF), 6-minute walking distance (6MWT), CD3+, CD4+ T cells, natural killer cells, and IL-10 levels.
- The treatment group showed significant reductions in brain natriuretic peptide (BNP), high-sensitivity C-reactive protein (hsCRP), Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores, CD8+ T cells, TNF-α, and IL-1β.
- While left ventricular end-diastole (LVEDD) and end-systole (LVESD) diameters decreased in the treatment group, the difference between groups was not statistically significant.
Conclusions:
- Immune modulation therapy, specifically using thymopentin, effectively improves cardiac function in elderly patients with CHF.
- Thymopentin therapy helps regulate key lymphocyte subsets and inflammatory cytokine profiles, suggesting a beneficial immunomodulatory effect in CHF.
- These findings support immune modulation as a therapeutic strategy for improving outcomes in older adults with chronic heart failure.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
1.8K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K
01:22Heart Failure Drugs: β-Blockers
1.1K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
01:30Heart Failure V: Medical Management
465
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
465
01:29Cardiomyopathy V: Interprofessional Care
582
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
582
01:30Cardiomyopathy II: Dilated Cardiomyopathy
716
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
716
01:22Heart Failure VI: Adjunct Therapies
501
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
501